Allianz Asset Management GmbH acquired a new position in Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 120,450 shares of the biotechnology company’s stock, valued at approximately $4,366,000. Allianz Asset Management GmbH owned approximately 0.33% of Ascendis Pharma A/S at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of ASND. VHCP Management II LLC grew its position in Ascendis Pharma A/S by 31.7% during the 3rd quarter. VHCP Management II LLC now owns 1,299,052 shares of the biotechnology company’s stock valued at $47,091,000 after purchasing an additional 312,560 shares during the last quarter. Wells Fargo & Company MN grew its position in Ascendis Pharma A/S by 788.8% during the 3rd quarter. Wells Fargo & Company MN now owns 30,076 shares of the biotechnology company’s stock valued at $1,090,000 after purchasing an additional 26,692 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at about $372,000. JPMorgan Chase & Co. purchased a new stake in Ascendis Pharma A/S during the 3rd quarter valued at about $7,163,000. Finally, Alps Advisors Inc. grew its position in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 31,929 shares of the biotechnology company’s stock valued at $1,157,000 after purchasing an additional 2,665 shares during the last quarter. Institutional investors and hedge funds own 78.93% of the company’s stock.
Shares of Ascendis Pharma A/S (ASND) traded up $0.95 on Friday, reaching $46.58. 65,795 shares of the company’s stock were exchanged, compared to its average volume of 148,235. Ascendis Pharma A/S has a twelve month low of $19.95 and a twelve month high of $47.71. The stock has a market cap of $1,690.00 and a price-to-earnings ratio of -11.76.
A number of brokerages have recently issued reports on ASND. BidaskClub raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Bank of America raised their price target on shares of Ascendis Pharma A/S from $36.00 to $46.00 in a report on Thursday, September 28th. HC Wainwright reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research note on Wednesday, December 13th. Credit Suisse Group reiterated an “outperform” rating and issued a $50.00 price objective (up previously from $30.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. Finally, Wedbush reiterated an “outperform” rating and issued a $10.71 price objective (down previously from $65.00) on shares of Ascendis Pharma A/S in a research note on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $38.79.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/13/allianz-asset-management-gmbh-takes-position-in-ascendis-pharma-as-asnd.html.
Ascendis Pharma A/S Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.